NCATS Accepting Applications for CTSAProgram-Supported COVID-19 Research
Notice Number: NOT-TR-20-011
Key Dates
Release Date: March 24, 2020
First Available Due Date: May 04, 2020
Expiration Date: July 10, 2021
Related Announcements
NOT-TR-20-018 Notice of Change in Eligibility and Activity Codes for NOT-TR-20-011
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
PAR-19-099 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)
PAR-19-100 Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)
PAR-19-337 Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)
Purpose
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).
Background
Translating biomedical discoveries into clinical applications is essential to improving human health. It is also a complex process with high costs and substantial failure rates. These failures can result in delays of years or decades before improved patient outcomes result from discoveries in biomedical research. Under NCATS’ leadership, the CTSA Program supports a national consortium of medical research institutions that work together to tackle system-wide scientific and operational changes that solve the many outstanding problems limiting the efficiency, effectiveness, and reach of clinical translational research, and thus get more treatments to more patients more quickly across the country. To do that, the program focuses on widely appreciated systematic barriers.
Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, COVID-19, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (https://www.cdc.gov/coronavirus/index.html) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of the disease are poorly understood. Given this, there is an urgent public health need to better understand the COVID-19.
Application and Submission Information
This notice applies to receipt dates shown below.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice.
Activity Code UL1, U01, R21
FOA Title PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Applicable Receipt Dates:
- May 4, 2020
- November 2, 2020
Activity Code U01
FOA Title PAR-19-099 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)
Applicable Receipt Dates:
- July 10, 2020
- November 9, 2020
- March 8, 2021
- July 9, 2021
Activity Code R21
FOA Title PAR-19-100 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)
Applicable Receipt Dates:
- July 10, 2020
- November 9, 2020
- March 8, 2021
- July 9, 2021
Activity Code UL1
FOA Title PAR-19-337 - Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional).
Applicable Receipt Date:
- September 25, 2020
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
- Application Due Date(s) are due on the due date listed above by 5:00 PM local time of applicant organization
- For funding consideration, applicants must include the relevant FOA information “NOT-TR-20-011” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
- For submissions to PA-18-591, the process for Streamlined Submissions using the eRA Commons cannot be used for this initiative. In addition, Administrative supplement applications to PA-18-591 must use the application form package with the Competition ID of “FORMS-E-ADMINSUPP-RESEARCH". This FOA will be reissued with a “FORMS-F-ADMINSUPP-RESEARCH” package on May 25, 2020. Submissions to PA-18-591 must be completed by June 25, 2020 (see NOT-OD-20-026 for details.) Submissions to the reissued FOA will be accepted on or after May 25, 2020 through the expiration date of this Notice.
Note concerning the Award Project Period: Supplement project and budget periods are limited to the remaining active budget period that started in the current fiscal year for the existing parent award. To be eligible, the parent award must be active (i.e., not be in an extension period), and the activities proposed in the supplement must be accomplished within the remaining active budget period that started in the current fiscal year for the existing parent award.
Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.
Inquiries
Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed funding opportunity announcements.